May 23, 2022
Article
The investigators concluded that a phase 3 trial is warranted.
May 18, 2022
Article
Investigators reported that all responders had FGFR3 mutations and that most non-responders had a prior history of bladder cancer, with 1 patient having a FGFR3-TACC3 fusion.
February 21, 2022
Article
The investigators concluded that time to event end points and response rates were similar regardless of which first-line immunotherapy was administered.
February 19, 2022
Article
The combo of the PARP inhibitor niraparib and the multikinase inhibitor cabozantinib showed positive early efficacy and safety signals in patients with metastatic urothelial carcinoma or renal cell carcinoma.